Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results

Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results

Survival outcomes in ovarian cancer are poor. The aims of this Phase I progressive design study (NCT02903771) were to evaluate the maximum tolerated dose (MTD), tolerability, and antitumor activity of Cantrixil—a novel third-generation benzopyran molecule—in patients (<i>n</i> = 25) with...

Full description

Bibliographic Details
Main Authors: Jermaine I. Coward, Minal A. Barve, Ganessan Kichenadasse, Kathleen N. Moore, Paul R. Harnett, Daniel Berg, James S. Garner, Don S. Dizon
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
ovarian cancer
platinum refractory
platinum resistant
intraperitoneal delivery
phase I
Online Access:https://www.mdpi.com/2072-6694/13/13/3196

Internet

https://www.mdpi.com/2072-6694/13/13/3196

Similar Items